Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11337 - 11344 of 12007 results
D.C. Circuit Rejects Length of Purdue Executives' Exclusion but Remands for Reconsideration
July 29, 2012| Blog| Viewpoint
Morbid Obesity as a Covered Disability under the ADA
July 27, 2012| Blog| Viewpoint
Public-Private Partnership to Fight Fraud Formed
July 27, 2012| Blog| Viewpoint
Law & Order PEPU: California's new Privacy Enforcement and Protection Unit
July 27, 2012| Blog| Viewpoint
Noncompete Agreements: New NH Law Restricts Enforcement
July 24, 2012| Blog| Viewpoint
Court Rules on What is "Commercially Reasonable" Bank Security
July 19, 2012| Blog| Viewpoint
Know thy vendor's vendor.....
July 18, 2012| Blog| Viewpoint
The Affordable Care Act, Stand-Alone Health Reimbursement Accounts, and the Prospects for Consumer-Driven Health Plans
July 17, 2012| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|